New Drug Approved: Revolutionary Treatment for Metastatic Hormone-Sensitive Prostate Cancer, Mexico

Darolutamide, a new drug approved by the Federal Commission for the Protection against Sanitary Risks (Cofepris), has shown promising results in treating metastatic hormone-sensitive prostate cancer (mHSPC). It reduces the risk of death by more than 30% and slows down the progression of the disease. Prostate cancer is common in Latin America and the Caribbean, with a high number of cases and deaths reported each year. The causes of the disease are unknown, but age is a significant risk factor. The lack of specific symptoms often leads to late detection. Some cases of prostate cancer become resistant to conventional hormone therapy, requiring alternative treatment approaches. Darolutamide, part of a triple therapy approach, has gained attention for its effectiveness and low risk of adverse effects. The recent approval in Mexico offers hope to patients with metastatic hormone-sensitive prostate cancer in the country, where it is the deadliest tumor among men. This new treatment option provides a chance for longer life and improved quality for patients.